• LAST PRICE
    0.9200
  • TODAY'S CHANGE (%)
    Trending Down-0.0300 (-3.1579%)
  • Bid / Lots
    0.7500/ 30
  • Ask / Lots
    1.0200/ 1
  • Open / Previous Close
    0.9450 / 0.9500
  • Day Range
    Low 0.9120
    High 0.9791
  • 52 Week Range
    Low 0.6600
    High 7.9589
  • Volume
    11,263
    below average

Search Criteria

Filter search criteria using below inputs

Click on magnifying glass icon to search

Search Criteria - - - Stocks (0)
CompanyCountrySymbol
Select an index
Price Comparison Graph. See accessible table below
1 Day Comparison Chart Accessibility Table. Thursday's close: 0.95
TimeVolumeTCRT
09:43 ET6520.96305
10:21 ET1200.912001
10:30 ET1000.92
10:48 ET2000.918365
10:51 ET4000.92
11:00 ET2000.966
11:04 ET21720.9791
11:08 ET2090.9506
11:49 ET1000.9353
11:56 ET1000.9353
12:02 ET4090.9236
12:21 ET1000.950599
12:27 ET1000.9506
12:43 ET3690.9207
12:57 ET7440.9505
03:20 ET7110.92
03:45 ET3000.92
03:50 ET4680.92
03:54 ET13000.9306
03:56 ET1450.9201
03:57 ET5110.92
Data delayed at least 15 minutes.
No documents available
0 New Today
Industry Peers Overview Table
Company sortableMarket Cap sortableP/E Ratio (TTM) sortableEPS Growth (5yr) sortable
United StatesTCRT
Alaunos Therapeutics Inc
14.7M
-0.5x
---
United StatesNBIO
Nascent Biotech Inc
14.8M
-5.9x
---
United StatesGLTO
Galecto Inc
14.4M
-0.5x
---
United StatesEDSA
Edesa Biotech Inc
14.3M
-1.9x
---
United StatesVICP
Vicapsys Life Sciences Inc
14.2M
-13.6x
---
United StatesKPRX
Kiora Pharmaceuticals Inc
15.9M
-0.4x
---
As of 2024-06-15

Company Information

Alaunos Therapeutics, Inc. is a clinical-stage oncology-focused cell therapy company. The Company is focused on exploring strategic alternatives, including, but not limited to, an acquisition, merger, reverse merger, sale of assets, strategic partnerships, capital raises or other transactions. Separately, the Company is evaluating several potential in-licensing opportunities in obesity, oncology and virology.

Contact Information

Headquarters
2617 Bissonnet St, Suite 225HOUSTON, TX, United States 77005
Phone
617-259-1970
Fax
617-241-2855

Executives

Independent Chairman of the Board
Holger Weis
Interim Chief Executive Officer, Director
Dale Hogue
Vice President - Finance
Ferdinand Groenewald
Independent Director
Robert Hofmeister
Independent Director
Robert Postma

Our Ratings feature offers company-specific research ratings from providers such as First Call, S&P and Argus.

Open a New Account, or Login if you're a client.

You have access to a comprehensive selection of independent research reports from providers such as TD Securities, S&P, INK, and Argus.

Open a New Account, or Login if you're a client.

Fundamentals Table
Market Cap
$14.7M
Revenue (TTM)
$6.0K
Shares Outstanding
16.0M
Dividend Yield
0.00%
Annual Dividend Rate
---
Ex-Dividend Date
01-01-01
Pay Date
01-01-01
Beta
-0.46
EPS
$-1.67
Book Value
$0.39
P/E Ratio
-0.5x
Price/Sales (TTM)
2,455.3
Price/Cash Flow (TTM)
---
Operating Margin
-438,950.00%
*GAAP = prior to non-GAAP analyst adjusted earnings.

Our Calendar feature allows you to view a wide selection of market and company events, including earnings, dividends, splits, rating changes, guidance, and more. Access past, current and future events in WebBroker.

Open a New Account, or Login if you're a client.